An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors

drug protocol number

B7841007

drug sponsor

Pfizer / MCT

drug study

Marstacimab

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh)

drug status

Ongoing

drug phase